Revenue barely registers for a $1.7 billion market cap, and it does not matter: the whole stock rides on 13-week interim hair-loss data from the HEADLINE trial of ABS-201 due in December, with full 26-week results early next year. Cash of $173.7 million funds operations into the second half of 2028, so the December readout sets the next move.
Latest Activity
Absci reports before the open with no beat streak intact, having landed on the right side of estimates just twice in the last four quarters. Consensus sits at a loss of $0.20 per share, so the AI drug-discovery story turns on pipeline and partnership commentary.
ABSI Coverage
AMD’s $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
AMD just filed its first-ever 13F, and buried inside a $1.31 billion portfolio are five positions that trace exactly where the company believes AI infrastructure spending lands next, including one ticker most…
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…